I am submitting an application on behalf of Nintedanib ( Vargatef) to the SMC, (Scotland's equivalent of NICE) for the treatment of advanced NSCLC as a second line treatment in combination with Docetaxel following first line treatment with a platinum based therapy. I am looking to support my application with accounts of people who have experience of using the treatment, perhaps as part of a trial? You can email me directly at beth.cochrane@roycastle.org or reply below.
Many thanks,
Beth, on behalf of information and support.